Navigation Links
Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
Date:12/7/2011

BOONTON, N.J., Dec. 7, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will be presenting a corporate overview at the 22nd Annual Oppenheimer Healthcare Conference being held in New York City.  Mr. Palmer's live presentation is scheduled to begin at 4:10 p.m. ET on Tuesday, December 13, 2011.

A live webcast of the presentation will be available by logging on to the Investors and Media section under the Events tab of the Unigene web site, http://www.unigene.com. Participants should allow approximately five to 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.

About Unigene Laboratories, Inc.:
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
jrando@tiberend.com / amielach@tiberend.com


'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
2. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
3. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
4. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
5. Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
8. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
9. Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
10. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Crucial Life Sciences Data Solutions, ... greatly improves performance of the platform. In particular, Version 4.1 boosts performance for ... data to be collected on a per patient basis. Clinical Studio has employed ...
(Date:5/5/2016)... ... May 05, 2016 , ... American Process, Inc. (API) announced ... Patent Nos. 9,322,133 and 9,322,134, to API and its affiliated companies for BioPlus® ... hydrophobic nanocellulose compositions. In addition to these patents and U.S. Patent No. ...
(Date:5/4/2016)... , ... May 05, 2016 , ... ... proud to support the National Stroke Association during National Stroke Awareness Month in ... Facebook and Twitter pages throughout the month. CereScan will donate $1 up ...
(Date:5/4/2016)... WHIPPANY, N.J. , May 4, 2016 /PRNewswire/ ... evaluating its oncology compound Stivarga ® (regorafenib) ... hepatocellular carcinoma (HCC) has met its primary endpoint ... The study, called RESORCE, evaluated the efficacy and ... disease has progressed after treatment with sorafenib. The ...
Breaking Biology Technology:
(Date:3/10/2016)... 10, 2016   Unisys Corporation (NYSE: UIS ... (CBP) is testing its biometric identity solution at the ... to help identify certain non-U.S. citizens leaving the country. ... designed to help determine the efficiency and accuracy of using ... and will run until May 2016. --> ...
(Date:3/9/2016)... -- Nigeria . Recently, the ... public service employees either did not exist with their ...    --> Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> DERMALOG, the biometrics innovation ...
(Date:3/8/2016)... RALEIGH, N.C. , March 8, 2016 /PRNewswire/ ... biometric sensor technology, today announced it has secured ... led by GII Tech, a new venture fund ... LLC, with additional participation from existing investors TDF ... use the funds to continue its triple-digit growth ...
Breaking Biology News(10 mins):